TAS0612, a Novel RSK, AKT, and S6K Inhibitor, Exhibits Antitumor Effects in Preclinical Tumor Models

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways are crucial for cancer progression.
• Single-agent inhibitors targeting these pathways have limited clinical efficacy due to resistance mechanisms like feedback signaling and receptor tyrosine kinase (RTK) reexpression.

Purpose of the Study:

• To identify and characterize a novel kinase inhibitor, TAS0612, with potential to overcome resistance in cancer therapy.
• To evaluate the efficacy of TAS0612 against various cancer models, particularly those with specific genetic alterations.

Main Methods:

• In vitro characterization of TAS0612's kinase inhibitory profile, including RSK, AKT, and S6K.
• Assessment of TAS0612's growth inhibitory effects on cancer cell lines with genetic abnormalities (e.g., PTEN loss/mutations).
• Evaluation of TAS0612's antitumor activity in preclinical tumor models, comparing it with existing pathway inhibitors.

Main Results:

• TAS0612 potently inhibits RSK, AKT, and S6K, showing strong correlation with growth inhibition in cancer cells with PTEN loss/mutations.
• TAS0612 demonstrates broad-spectrum activity, outperforming single-pathway inhibitors (AKT, PI3K, MEK, BRAF, EGFR/HER2) in relevant tumor models.
• TAS0612 effectively blocks downstream signals and overcomes resistance mechanisms, including HER3 reexpression, unlike other inhibitors.

Conclusions:

• TAS0612 is a potent, orally available kinase inhibitor with significant preclinical antitumor activity.
• Its unique inhibitory profile, including RSK activity, differentiates it from PI3K-only inhibitors and may overcome resistance.
• TAS0612 represents a promising novel therapeutic strategy for improving clinical responses in cancer patients by targeting multiple key pathways and resistance mechanisms.